medigraphic.com
ISSN 0016-3813 (Impreso)

2014, Número 1

<< Anterior Siguiente >>

Gac Med Mex 2014; 150 (1)


Cáncer diferenciado de tiroides: una antigua enfermedad con nuevos conocimientos

Granados GM, León TAM, Guerrero HFJ, Taissoun AZA

Idioma: Español
Referencias bibliográficas: 98
Paginas: 65-77
Archivo PDF: 283.58 Kb.


RESUMEN

El cáncer diferenciado de tiroides es la neoplasia endocrina más común y su incidencia parece aumentar rápidamente, aunque con un buen pronóstico; la participación de diversas especialidades médicas ha propiciado diferentes enfoques en el tratamiento e incluso varias controversias. En ausencia de estudios controlados, las recomendaciones para el tratamiento se fundamentan en conocer los factores pronósticos para la sobrevida y el control local, los efectos de los tratamientos y la morbilidad asociada. Recientemente, se han presentado avances importantes en el área de la genética y la biología molecular que tienen aplicaciones terapéuticas principalmente para la enfermedad refractaria al yodo; también se han logrado avances en el tratamiento adyuvante utilizando radiofármacos y hormonas recombinantes. Con toda esta nueva información, presentamos una revisión que pretende actualizar los conocimientos sobre una enfermedad antigua.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. [Internet] Disponible en: http://globocan.iarc.fr/factsheet.asp

  2. Morris LG, Sikora AG, Tosteson TD, Davies L. The Increasing Incidence of Thyroid Cancer: The Influence of Access to Care. Thyroid. 2013;23(7):885-91.

  3. Malchoff CD, Malchoff DM. Familial nonmedullary thyroid carcinoma. Sem Surg Oncol. 1999;16:16-8. Gaceta Médica de México. 2014;150 76

  4. Leeman-Neill RJ, Brenner AV, Little MP, et al. RET/PTC and PAX8/PPARγ chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics. Cancer. 2013;119(10):1792-9.

  5. Romei C, Ciampi R, Faviana P, et al. BRAFV600E mutation, but not RET/ PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr Relat Cancer. 2008;15(2):511-20.

  6. Knauf JA, Ma X, Smith EP, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 2005;65(10):4238-45.

  7. Liu D, Hu S, Hou P, Jiang D, Condouris S, Xing M. Suppression of BRAF/ MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res. 2007;13(4):1341-9.

  8. Ho al, Grewal RK, Leboeuf R, et al. Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer. N Engl J Med. 2013;368 (7):623-32.

  9. Lacroix L, Soria JC, Bidart JM, Schlumberger M. Oncogènes et tumeurs de la thyroïde. Bull Cancer. 2005;92(1):37-43.

  10. Romitti M, Ceolin L, Siqueira DR, Ferreira CV, Wajner SM, Maia AL. Signaling pathways in follicular cell-derived thyroid carcinomas. Int J Oncol. 2013;42(1):19-2.

  11. Silver CE, Owen RP, Rodrigo JP, Rinaldo A, Devaney KO, Ferlito A. Aggressive variants of papillary thyroid carcinoma. Head Neck. 2011;33(7):1052-9.

  12. Yamashina M. Follicular neoplasms of the thyroid. Total circumferential evaluation of the fibrous capsule. Am J Surg Pathol. 1992;16:392-400.

  13. Franssila KO, Ackerman LV, Brown CL, Hedinger CE. Follicular carcinoma. Sem Diagn Pathol. 1985;2:101-22.

  14. Davidson HC, Park BJ, Johnson JT. Papillary thyroid cancer: controversies in the management of neck metastasis. Laryngoscope. 2008;118(12):2161-5.

  15. Song HJ, Xue YL, Qiu ZL, Luo QY. Uncommon metastases from differentiated thyroid carcinoma. Hell J Nucl Med. 2012;15(3):233-40.

  16. Shattuck T, Westra W, Larderson PW, Arnold A. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. New Eng J Med. 2005;352:2406-12.

  17. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery. 1987;102(6):1088-94.

  18. Emerick GT, Duh QY, Saperstein AE, Burrow GN, Clark OH. Diagnosis, treatment, and outcome of follicular thyroid carcinoma. Cancer. 1993;72:3287-95.

  19. Vander JB, Gaston EA, Dawber TR. The significance of nontoxic thyroid nodules: final report of a 15-year study of the incidence of thyroid malignancy. Ann Intern Med. 1968;69:537-40.

  20. Turnbridge WMG, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol. 1977;7:481-93.

  21. Seningen JL, Nassar A, Henry MR. Correlation of thyroid nodule fineneedle aspiration cytology with corresponding histology at Mayo Clinic, 2001-2007: an institutional experience of 1,945 cases. Diagn Cytopathol. 2012;40 Suppl 1:E27-32.

  22. Yoon JH, Kwak JY, Moon HJ, Kim MJ, Kim EK. The diagnostic accuracy of ultrasound-guided fine-needle aspiration biopsy and the sonographic differences between benign and malignant thyroid nodules 3 cm or larger. Thyroid. 2011;21(9):993-1000.

  23. Gharib H. Fine–needle aspiration biopsy of thyroid nodules: advantage, limitations, and effect. Mayo Clin Proc. 1994;69:44-9.

  24. Jogai S, Al-Jassar A, Temmim L, Dey P, Adesina AO, Amanguno HG. Fine needle aspiration cytology of the thyroid: a cytohistologic study with evaluation of discordant cases. Acta Cytol. 2005;49(5):483-8.

  25. Cañadas-Garre M, Becerra-Massare P, López de la Torre-Casares M, et al. Reduction of False-Negative Papillary Thyroid Carcinomas by the Routine Analysis of BRAFT1799A Mutation on Fine-Needle Aspiration Biopsy Specimens: A Prospective Study of 814 Thyroid FNAB Patients. Ann Surg. 2012;255(5):986-92.

  26. Cibas E, Ali SZ. The Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2009;19(11):1159-65.

  27. Richmond BK, O’Brien BA, Mangano W, Thompson S, Kemper S. The impact of implementation of the Bethesda System for Reporting Thyroid Cytopathology on the surgical treatment of thyroid nodules. Am Surg. 2012;78(6):706-10.

  28. Adamczewski Z, Lewi Ski A. Proposed algorithm for management of patients with thyroid nodules/focal lesions, based on ultrasound (US) and fine-needle aspiration biopsy (FNAB); our own experience. Thyroid Res. 2013;6(1):6.

  29. Li QK, Nugent SL, Straseski J, et al. Thyroglobulin measurements in fine-needle aspiration cytology of lymph nodes for the detection of metastatic papillary thyroid carcinoma. Cancer Cytopathol. 2013;121(8):440-8.

  30. Horvath E, Majlis S, Rossi R, et al. An Ultrasonogram Reporting System for Thyroid Nodules Stratifying Cancer Risk for Clinical Management. J Clin Endocrinol Metab. 2009;90:1748-51.

  31. Urhan M, Velioglu M, Rosenbaum J, Basu S, Alavi A. Imaging for the diagnosis of thyroid cancer. Expert Opin Med Diagn. 2009;3(3):237-49.

  32. Elisei R, Bottici V, Luchetti F, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10864 patients with nodular thyroid disorders. J Clin Endocrinol Metab. 2004;89(1):163-8.

  33. Cady B, Rossi R. An expanded view of risk group definition in differentiated thyroid carcinoma. Surgery.1988;104:947-53.

  34. Schneider DF, Chen H, Sippel RS. Impact of Lymph Node Ratio on Survival in Papillary Thyroid Cancer. Ann Surg Oncol. 2013;20(6):1906-11.

  35. Grant CS, Hay D. Local recurrence of papillary thryroid carcinoma after unilateral or bilateral thyroidectomy. Wien Klin Wochenschr. 1988;100(11):342-6.

  36. Fernandez IJ, Piccin O, Sciascia S, et al. Clinical Significance of BRAF Mutation in Thyroid Papillary Cancer. Otolaryngol Head Neck Surg. 2013;148(6):919-25.

  37. Oyer SL, Smith VA, Lentsch EJ. Sex is not an independent risk factor for survival in differentiated thyroid cancer. Laryngoscope. 2013. [Epub ahead of print]

  38. Silver CE, Owen RP, Rodrigo JP, Rinaldo A, Devaney KO, Ferlito A. Aggressive variants of papillary thyroid carcinoma. Head Neck. 2011; 33(7):1052-9.

  39. Kazaure HS, Roman SA, Sosa JA. Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients. Ann Surg Oncol. 2012;19(6):1874-80.

  40. Sorrenti S, Trimboli P, Catania A, Ulisse S, De Antoni E, D’Armiento M. Comparison of malignancy rate in thyroid nodules with cytology of indeterminate follicular or indeterminate Hürthle cell neoplasm. Thyroid. 2009;19(4):355-60.

  41. American Joint Committee on Cancer Staging Handbook. 7.a ed. Nueva York: Springer; 2010. p. 111-22.

  42. Shaha A, Shah JP, Loreé TR. Low risk differentiated thyroid cancer. The need for selective treatment. Ann Surg Oncol. 1997;4:328-33.

  43. Mazzaferri EL, Jhiang SL. Long term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418-28.

  44. Granados-García M, Cortés-Flores AO, del Carmen González-Ramírez I, Cano-Valdez AM, Flores-Hernández L, Aguilar-Ponce JL. Follicular neoplasms of the thyroid: importance of clinical and cytological correlation. Cir Cir. 2010;78(6):473-8.

  45. Horvath E, Majlis S, Rossi R, et al. An Ultrasonogram Reporting System for Thyroid Nodules Stratifying Cancer Risk for Clinical Management. J Clin Endocrinol Metab. 2009;90:1748-51.

  46. Cañadas-Garre M, Becerra-Massare P, López de la Torre-Casares M, et al. Reduction of False-Negative Papillary Thyroid Carcinomas by the Routine Analysis of BRAFT1799A Mutation on Fine-Needle Aspiration Biopsy Specimens: A Prospective Study of 814 Thyroid FNAB Patients. Ann Surg. 2012;255:986-92.

  47. Goh HK, Ng YH, Teo DT. Minimally invasive surgery for head and neck cancer. Lancet Oncology. 2010;11:281-6.

  48. Timon C, Miller IS. Minimally invasive video-assisted thyroidectomy: indications and technique. Laryngoscope. 2006;116:1046-9.

  49. Shimizu K. Minimally invasive thyroid surgery. Clin Endocrinol Metab. 2001;15:123-37.

  50. Inabnet WB, Jacob BP, Gagner M. Minimally invasive endoscopic thyroidectomy by a cervical approach. Surg Endosc. 2003;17:1808-11.

  51. Miccoli P, Berti P, Materazzi G, Minuto M, Barellini L. Minimally invasive video-assisted thyroidectomy: five years of experience. J Am Coll Surg. 2004;199(2):243-8.

  52. Perigli G, Cortesini C, Qirici E, Boni D, Cianchi F. Clinical benefits of minimally invasive techniques in thyroid surgery. World J Surg. 2008;32(1):45-50.

  53. Kitigawa W, Shimizu K, Akasu H, Tanaka S. Endoscopic neck surgery with lymph node dissection for papillary carcinoma of the thyroid using a totally gasless anterior neck skin lifting method. J Am Coll Surg. 2003;196(6):990-4.

  54. Chung YS, Choe JH, Kang KH, et al. Endoscopic thyroidectomy for thyroid malignancies: comparison with conventional open thyroidectomy. World J Surg. 2007;31(12):2302-6.

  55. Sang-Wok K, Jong Ju J, Ji-Sup Y, et al. Robot-assisted endoscopic surgery for thyroid cancer: experience with the first 100 patients. Surg Endosc. 2009;23(11):2399-406.

  56. Barczynski M, Konturek A, Stopa M, Nowak W. Prophylactic central neck dissection for papillary thyroid cancer. Br J Surg. 2013;100(3):410-8.

  57. Palestini N, Borasi A, Cestino L, Freddi M, Odasso C, Robecchi A. Is central neck dissection a safe procedure in the treatment of papillary thyroid cancer? Our experience. Langenbecks Arch Surg. 2008;393(5): 693-8.

  58. Son YI, Jeong HS, Baek CH, et al. Extent of Prophylactic Lymph Node Dissection in the Central Neck Area of the Patients with Papillary Thyroid Carcinoma: Comparison of Limited Versus Comprehensive Lymph Node Dissection in a 2-Year Safety Study. Ann Surg Oncol. 2008;15(7): 2020-6. 77

  59. Vásquez-Ciriaco S, Granados-García M, Luna-Ortiz K, et al. Assessment of morbidity of central neck compartment dissection in papillary thyroid cancer. Cir Gen. 2011;33:111-11.

  60. Raffaelli M, De Crea C, Sessa L, et al. Prospective evaluation of total thyroidectomy versus ipsilateral versus bilateral central neck dissection in patients with clinically node-negative papillary thyroid carcinoma. Surgery. 2012;152(6):957-64.

  61. Yu WB, Tao SY, Zhang NS. Is level V dissection necessary for low-risk patients with papillary thyroid cancer metastasis in lateral neck levels II, III, and IV. Asian Pac J Cancer Prev. 2012;13(9):4619-22.

  62. Beasley NJP, Lee J, Eski S, Walfish P, Witterick I, Freeman J. Impact of nodal metastases on prognosis in patients with well –differentiated thyroid Cancer. Arch Otolaryngol Head Neck Surg. 2002;128:825-8.

  63. Lee SK, Choi JH, Lim HI, et al. Sentinel lymph node biopsy in papillary thyroid cancer: Comparison study of blue dye method and combined radioisotope and blue dye method in papillary thyroid cancer. Eur J Surg Oncol. 2009;35(9):974-9.

  64. Honings J, Stephen AE, Marres HA, Gaissert HA. The Management of Thyroid Carcinoma Invading the Larynx or Trachea. Laryngoscope. 2010;120:682-9.

  65. McCaffrey TV, Bergstrahl E, Hay I. Locally invasive papillary thyroid cancer. Head Neck. 1994;16:165-72.

  66. McCaffrey JC. Aerodigestive Tract Invasion by Well- Differentiated Thyroid Carcinoma: Diagnosis, Management, Prognosis, and Biology. Laryngoscope. 2006;116(1):1-11.

  67. Nishida T, Nakao K, Hashimoto T. Local control in differentiated thyroid carcinoma with extrathyroidal invasion. Am J Surg. 2000;179:86-91.

  68. Czaja JM, McCaffrey TV. The surgical management of laringotraqueal invasion by well differentiated papillary thyroid cancer. Arch Otolaryngol Head Neck Surg. 1997;123:484-90.

  69. Shin DH, Mark EJ, Suen HC, Grillo HC. Pathologic staging of papillary carcinoma of the thyroid with airway invasion based on the anatomic manner of extension to the trachea. Hum Pathol. 1993;24:866-70.

  70. Kim KH, Sung MW, Chang KH, Kang BS. Therapeutic dilemmas in the management of thyroid cancer with laryngotracheal involvement. Otolaryngol Head Neck Surg. 2000;122:763-7.

  71. Gaissert HA, Honings J, Grillo HC, et al. Segmental laryngotracheal and tracheal resection for invasive thyroid carcinoma. Ann Thorac Surg. 2007;83:1952-9.

  72. Cody HS, Shah JP. Locally invasive, well-differentiated thyroid cancer. 22 year’s experience at Memorial Sloan_ Kettering Cancer Center. Am J Surg. 1981;142:480-3.

  73. McCaffrey TV, Bergstrahl E, Hay I. Locally invasive papillary thyroid cancer: 1940-1990. Head Neck. 1994;16(2):165-72.

  74. Musholt TJ, Musholt PB, Behrent M, Raab R, Scheumann GFW, Klepnauer J. Invasive differentiated thyroid carcinoma: traqueal resection and reconstruction procedures in the hands of the endocrine surgeon. Surgery. 1999;126:1078-88.

  75. Yang CC, Lee CH, Wang LS, Huang BS, Hsu WH, Huang MH. Resectional treatment for Thyroid cancer with tracheal invasion. Arch Surg. 2000;135:704-7.

  76. Grillo HC, Suen HC, Mathisen DJ, Wain JC. Resectional management of thyroid carcinoma invading the airway. Ann Thoracic Surg. 1999;54:3-10.

  77. Kim TH, Yang DS, Jung KY, Kim CY, Choi MS. Value of external irradiation for locally advanced papillary thyroid cancer. Int J Radiat Oncol Biol Phys. 2003;55(4):1006-12.

  78. Mazzaferry EL, Massoli N. Management of papillary and follicular (differentiated) Thyroid cancer: new paradigms using recombinant human thyrotropin. Endocr Relat Cancer. 2002;9(4):227-47.

  79. Hilditch TE, Dempsey MF, Bolster AD, Mc Nenemin RM, Reeed NS. Self –Stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123 I. Eur J Nucl Med. 2002;29:783-8.

  80. Schlumberger M, Catargi B, Borget I, et al. Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer. N Engl J Med. 2012;366:1663-73.

  81. Mallick U, Harmer C, Yap B, et al. Ablation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid Cancer. N Engl J Med. 2012; 366:1674-85.

  82. Robbins RJ, Tuttle M, Sharaf RN, et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal is comparable for detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2001;86(2):619-25.

  83. Robbins RJ, Tuttle M, Sonenberg M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid. 2001;11:865-9.

  84. Robbins RJ, Tuttle M, Sonenberg M, et al. M. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid. 2001;11:865-9.

  85. Luster M, Lippi F, Jarzab B, et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer. 2005;12(1):49-64.

  86. Nicolaides PN, Coatesworth AP. Thyroid cancer review 2: management of differentiated thyroid cancer. Int J Clin Pract. 2005;59:1459-63.

  87. Lee J, Yun MJ, Nam KH, Chung WY, Soh EY, Park CS. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid. 2010;20(2):173-9.

  88. Hugo J, Robenshtok E, Grewal R, Larson S, Tuttle RM. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence. Thyroid. 2012;22(10):1007-15.

  89. Tsang RW, Brierley JD, Simpson WJ, Panzarella T, Godsporadowicks MK, Sutcliffe SB. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer. 1998;82:375-88.

  90. Zettinig G, Fueger BJ, Passler C, et al. Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma – surgery or conventional therapy? Clin Endocrinol. 2002;56(3):377-82.

  91. Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer. N Engl J Med. 2013;368:623-32.

  92. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II Trial of Sorafenib in Advanced Thyroid Cancer. J Clin Oncol. 2008;26(29):4714-9.

  93. Brose MS. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase II DECISION trial. Presented at the 2013 ASCO annual meeting.

  94. Dulgeroff AJ, Hershman JM. Medical therapy for differentiated thyroid carcinoma. Endocr Rev. 1994;15(4):500-15.

  95. Giovanella L, Ceriani L, Ghelfo A, et al. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures. Clin Chem Lab Med. 2006;44(5):648-52.

  96. Malandrino P, Latina A, Marescalco S, et al. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin. J Clin Endocrinol Metab. 2011;96(6):1703-9.

  97. Tsushima Y, Miyauchi A, Ito Y, et al. Prognostic significance of changes in serum thyroglobulin antibody levels of pre- and post-total thyroidectomy in thyroglobulin antibody-positive papillary thyroid carcinoma patients. Endocr J. 2013;60(7):871-6.

  98. Weber T, Ohlhauser D, Hillenbrand A, Henne-Bruns D, Reske SN, Luster M. Impact of FDG-PET computed tomography for surgery of recurrent or persistent differentiated thyroid carcinoma. Horm Metab Res. 2012;44(12):904-8.




2020     |     www.medigraphic.com